Alexion Pharmaceuticals, Inc.

Endece LLC

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Amersham Pharmacia Biotech, Inc.

Steven H Nye

Stephen P Squinto

Louis A Matis

James G Yarger

James A Wilkins

Eileen Elliott Mueller

Russell P Rother

Scott A Rollins

Michael J Lenardo

Mark James Evans

Jeremy P Springhorn

Henry McFarland

John P Mueller

Eve Y Ting

Thomas C Thomas

Clara M Pelfrey

Barbara F Kaboord

Susan J Fly

William A Riedl

Yi Wang

Eileen Mueller

Disclosed is a method of remyelinating axons with 6-substituted estradiol compounds of the formula  The methods can be used to treat a variety of demyelinating diseases.

6-substituted estradiol derivatives for use in remyelination of nerve axons

Disclosed herein are 6-substituted 13-demethyl-estradiol derivatives as selective ER&#x3b2; agonists. Also disclosed is a method for treating pain by administering these 6-substituted 13-demethyl-estradiol derivatives.

6-substituted demethyl-estradiol derivatives as selective ER-&#x3b2; agonists

Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.

Modified myelin basic protein molecules

The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.

C5-specific antibodies for the treatment of inflammatory diseases

A Thermococcus barosii DNA polymerase with reduced 3'-5' exonuclease activity is disclosed. Additionally disclosed is a Thermococcus barosii DNA polymerase with increased ability to incorporate ribonucleotides and dideoxynucleotides.

Thermococcus barossii DNA polymerase mutants

Growing community of inventors

Mequon, WI, United States of America

Steven H Nye